WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)

WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)

Saved in:

Bibliographic Details
Main Authors:	Lisa Kivman, Tabea Kraft, Julia Rauser, Rainer Boxhammer, Stefan Hartle, Brian Schwartz, Paul Manser, Leslie Chinn, Uptal Patel, Donna Flesher, Krzysztof Kiryluk, Jonathan Barratt
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924023763
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-843 FELZARTAMAB REDUCES aPLA2R Ab BY SELECTIVELY DEPLETING CD38+ PLASMA CELLS AND PLASMABLASTS, THE MAIN PATHOGENIC CELLULAR DRIVERS OF DISEASE IN PRIMARY MEMBRANOUS NEPHROPATHY (PMN)
by: Donna Flesher, et al.
Published: (2025-02-01)

WCN25-844 FELZARTAMAB FOR IgA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY
by: Uptal Patel, et al.
Published: (2025-02-01)

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2025-02-01)

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-2522 ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-744 FELZARTAMAB SELECTIVELY AND POTENTLY TARGETS CD38+ ANTIBODY SECRETING CELLS FROM PATIENTS WITH IMMUNE-MEDIATED KIDNEY DISEASES
by: Kristina Ilieva, et al.
Published: (2025-02-01)

WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
by: Vlado Perkovic, et al.
Published: (2024-04-01)

2bRAD-M reveals circulating microbiome in chronic antibody-mediated rejection (CAMR) and IgA nephropathy (IgAN) after kidney transplantation
by: Yan-Xin Tao, et al.
Published: (2025-07-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy
by: Brad H. Rovin, et al.
Published: (2024-09-01)

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL
by: Richard Lafayette, et al.
Published: (2024-04-01)

WCN25-1084 INTERNATIONAL RISK-PREDICTION TOOL IN IgAN AND THE PROGNOSTIC IMPLICATIONS OF CRESCENTS
by: Beatriz Mendes, et al.
Published: (2025-02-01)

Enteric-coated Mycophenolate Sodium plus hydroxychloroquine therApy versus hydroxychloroquine for the Remission of Proteinuria in IgA Nephropathy (EMSAR-IgAN trial): study protocol for a randomised trial
by: Lihua Wang, et al.
Published: (2025-04-01)

WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
by: Vivekanand Jha, et al.
Published: (2025-02-01)

Novel Treatment Paradigms: Primary IgA Nephropathy
by: Haresh Selvaskandan, et al.
Published: (2024-02-01)

WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN25-4528 POST TRANSPLANT CRESCENTIC IgAN- FIRST CASE SERIES FROM INDIA
by: NITISH THAKUR, et al.
Published: (2025-02-01)

Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review
by: Sarah N. Ali, et al.
Published: (2025-05-01)

WCN24-2352 Improved Proteinuria Reduction with the use of Sparsentan and Targeted Release Budesonide in advanced IgAN
by: Neeharik Mareedu, et al.
Published: (2024-04-01)

Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy
by: Jincan Zan, et al.
Published: (2024-04-01)

IgG subclasses in symptomatic IgA deficiency
by: I Tezcan, et al.
Published: (1992-01-01)

WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

Relationship between Gd-IgA1 and TNFR1 in IgA nephropathy and IgA vasculitis nephritis in children – multicenter study
by: Małgorzata Mizerska-Wasiak, et al.
Published: (2021-08-01)

Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.
by: Qiang Sun, et al.
Published: (2016-01-01)

Carboxymethyl-lysine is a Prominent Target of Circulating IgA in IgA Nephropathy
by: Sara Alibrandi, et al.
Published: (2025-07-01)

Aberrantly Glycosylated IgA1 as a Factor in the Pathogenesis of IgA Nephropathy
by: Mototsugu Tanaka, et al.
Published: (2011-01-01)

Evaluation the Efficacy of ELISA IgG, IgM and IgA Tests for Diagnosis of Helicobacter pylori
by: Hogir Mohammed Shukri Saadi, et al.
Published: (2018-09-01)

IgA Nephropathy in the Elderly
by: Dana V. Rizk, et al.
Published: (2025-08-01)

Significance of serum IgA/C3 ratio in the diagnosis and prognosis of IgA nephropathy
by: XIE Wei-ji, et al.
Published: (2019-01-01)

Enzyme linked immunosorbent assay (ELISA) for detection of IgG, IgM, IgE and IgA against cysticercus cellulosae in cerebrospinal fluid in neurocysticercosis (abstract) Reações imunoenzimáticas para detecção de IgG, IgM, IgE e IgA anticisticerco no líquido cefalorraquiano na neurocisticercose (Resumo)
by: Newton Satoru Odashima
Published: (1997-09-01)

WCN24-1863 Towards an IgA Nephropathy Atlas
by: Julio Saez-Rodriguez, et al.
Published: (2024-04-01)

Evaluation of IgA and IgG Serology for the Detection of Helicobacter pylori Infection
by: Carlo A Fallone, et al.
Published: (1995-01-01)

Serum IgA/C3 ratio as a diagnostic and prognostic biomarker for IgA nephropathy
by: Anitha Swamy, et al.
Published: (2025-08-01)

Cellular Signaling and Production of Galactose-Deficient IgA1 in IgA Nephropathy, an Autoimmune Disease
by: Colin Reily, et al.
Published: (2014-01-01)

Clinical Significance of Serum Galactose-Deficient IgA1 Level in Children with IgA Nephropathy
by: Hitoshi Irabu, et al.
Published: (2020-01-01)